RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+6.51%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$251M
AUM Growth
–
Cap. Flow
+$251M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
29.9%
Holding
83
New
83
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$10.2M |
| 2 |
CELG
Celgene Corp
CELG
|
$8.28M |
| 3 |
Gilead Sciences
GILD
|
$8.19M |
| 4 |
CVS Health
CVS
|
$7.66M |
| 5 |
Biogen
BIIB
|
$7.55M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 84.16% |
| 2 | Financials | 1.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$61.5B
| $10.2M | 3.98% | +37,000 | New | +$10.2M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $8.28M | 3.24% | +49,000 | New | +$8.28M |
|
|
3
Gilead Sciences
GILD
$140B
| $8.19M | 3.2% | +109,000 | New | +$8.19M |
|
|
4
CVS Health
CVS
$92.8B
| $7.66M | 3% | +107,000 | New | +$7.66M |
|
|
5
Biogen
BIIB
$19.4B
| $7.55M | 2.95% | +27,000 | New | +$7.55M |
|
|
NPSP
6
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $7.29M | 2.85% | +240,000 | New | +$7.29M |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $7.03M | 2.75% | +100,000 | New | +$7.03M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $6.65M | 2.6% | +50,000 | New | +$6.65M |
|
|
PCYC
9
DELISTED
PHARMACYCLICS INC
PCYC
| $6.35M | 2.48% | +60,000 | New | +$6.35M |
|
10
Alkermes
ALKS
$4.78B
| $5.9M | 2.31% | +145,000 | New | +$5.9M |
|
|
AEGR
11
DELISTED
Aegerion Pharmaceuticals, Inc.
AEGR
| $5.32M | 2.08% | +75,000 | New | +$5.32M |
|
|
KERX
12
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $5.18M | 2.03% | +400,000 | New | +$5.18M |
|
|
SLXP
13
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $4.95M | 1.94% | +55,000 | New | +$4.95M |
|
|
ARIA
14
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $4.77M | 1.87% | +700,000 | New | +$4.77M |
|
15
Innoviva
INVA
$1.29B
| $4.71M | 1.84% | +132,000 | New | +$4.71M |
|
|
ESRX
16
DELISTED
Express Scripts Holding Company
ESRX
| $4.57M | 1.79% | +65,000 | New | +$4.57M |
|
17
Incyte
INCY
$16.5B
| $4.3M | 1.68% | +85,000 | New | +$4.3M |
|
18
Medtronic
MDT
$119B
| $4.3M | 1.68% | +75,000 | New | +$4.3M |
|
19
Merck
MRK
$210B
| $4.25M | 1.66% | +85,000 | New | +$4.25M |
|
20
Bristol-Myers Squibb
BMY
$96B
| $3.83M | 1.5% | +72,000 | New | +$3.83M |
|
21
UnitedHealth
UNH
$281B
| $3.31M | 1.3% | +44,000 | New | +$3.31M |
|
22
Boston Scientific
BSX
$156B
| $3.31M | 1.29% | +275,000 | New | +$3.31M |
|
|
FRX
23
DELISTED
FOREST LABORATORIES INC
FRX
| $3.3M | 1.29% | +55,000 | New | +$3.3M |
|
24
Intuitive Surgical
ISRG
$170B
| $3.07M | 1.2% | +8,000 | New | +$3.07M |
|
|
COV
25
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $3.07M | 1.2% | +45,000 | New | +$3.07M |
|